Decoding the Ubiquitin and Autophagy Signaling Networks
- Institution
- SLOAN-KETTERING INST CAN RESEARCH, NY
- Principal investigator
- Alban Ordureau
- Funding
- $440K
- Duration
- 2025–2029
Moonbase score
Still being scored
Abstract
ABSTRACT The research program described in this proposal focuses on an in-depth exploration of the ubiquitin and autophagy pathways, which partake in a process called proteome homeostasis, or proteostasis, and is an essential cellular process. Over the course of this proposal, our team aims to uncover novel aspects of molecular intricacies of ubiquitin regulation and to explore the mechanisms underlying selective autophagy in response to various cellular stimuli. Regarding the ubiquitin machinery aspect of our work, our goal is to identify and understand the cellular relevance of recently discovered regulatory switches for ubiquitin signaling. For the autophagy facet of our work, we aim to enhance our comprehension of singular regulatory factors we’ve identified, which are involved in this complex biological process. This program combines our expertise in quantitative mass spectrometry, biochemistry, and cell biology to investigate the different aspects of proteostasis dynamics and its disruption in proteostasis-related diseases. Our investigation aims not only to advance scientific knowledge but also to have a substantial impact on healthcare by reducing our current limitations in understanding disease mechanisms.
LOADING MOONBASE SCORE
Questions for SLOAN-KETTERING INST CAN RESEARCH
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Sloan-Kettering Inst Can ResearchNot yet scored
Mechanistic basis for endoplasmic reticulum-driven cytoprotection by selective autophagy in neurons
Alban Ordureau · $578K · 2024–2029
- NIH · Sloan-Kettering Inst Can Research60
Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient
Jesse Joshua Smith · $80K · 2025
- NIH · Sloan-Kettering Inst Can Research51
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
Ping Chi · $576K · 2022–2026